Marieke van Son

137 TOXICITY AFTER ULTRAFOCAL SALVAGE HDR-BRACHYTHERAPY 15. Slevin F, Hodgson S, Rodda SL, Bownes P, Bottomley D, Adiotomre E, et al. Effi- cacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent pros- tate cancer. Clinical and translational ra- diation oncology. 2020;23:20-6. 16. Chitmanee P, Tsang Y, Tharmalingam H, Hamada M, Alonzi R, Ostler P, et al. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recur- rent Prostate Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2020;32(4):259-65. 17. Kanthabalan A, Peters M, Van Vulpen M, McCartan N, Hindley RG, Emara A, et al. Focal salvage high-intensity fo- cused ultrasound in radiorecurrent prostate cancer. BJU international. 2017;120(2):246-56. 18. Bomers JGR, Overduin CG, Jenniskens SFM, Cornel EB, van Lin E, Sedelaar JPM, et al. Focal Salvage MR Imaging-Guid- ed Cryoablation for Localized Prostate Cancer Recurrence after Radiothera- py: 12-Month Follow-up. J Vasc Interv Radiol. 2020;31(1):35-41. 19. Scheltema MJ, van den Bos W, Siri- wardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-re- current prostate cancer. BJU interna- tional. 2017;120 Suppl 3:51-8. 20. Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, et al. Prostate high dose-rate brachytherapy as monothera- py for low and intermediate risk prostate cancer: Efficacy results from a random- ized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Ra- diother Oncol. 2020;146:90-6. 7